Sirolimus Eluting Coronary Stent System
Next Generation Biodegradable Polymer Technology
Sirolimus-eluting stent featuring a biodegradable polymer and a unique micro-porous PEARL surface, favours better endothelialisation and optimal drug delivery. With 10 years of clinical data, it demonstrates improved long-term performance compared to first-generation DES. The stent’s innovative 2-strut connector design ensures maximum flexibility and optimal side branch access, making it ideal for bifurcation stenting
Sirolimus
A clinically proven immunosuppressant, Sirolimus inhibits T and B cell activation via mTOR inhibition, reducing IL-2 sensitivity. Its anti-proliferative properties prevent restenosis when used with coronary stents.
Microporous Surface (PEARL)
The PEARL surface, combined with a biodegradable polymer, enhances endothelialization, reduces restenosis and thrombosis, and ensures controlled drug release, delivering optimal performance as a safe and effective DES technology.
Next-Generation Design
- CoCr platform with thin 68 μm struts for enhanced flexibility and deliverability.
- 2-connector design ensures excellent side-branch access for bifurcation stenting.
Abluminal Coating
Facilitates unidirectional drug release and less systemic exposure, ensuring improved healing & faster endothelialization.
Clinical Studies
10 Years of Robust Data Setting New Standards Longest-Studied DES Technology
In ACS patients, the Yukon stent demonstrated a lower 10-year POCE (65.3% vs. 69% for PP-DES) and a 23% reduced risk of total stent thrombosis.
The ISAR-TEST 4 trial’s 10-year follow-up reported the lowest rate of definite/probable stent thrombosis, showing a 50% risk reduction compared to the Cypher stent and a 29% lower rate compared to Xience.3
At 10 years, Yukon stent outcomes were comparable to Xience in patients with coronary artery disease, including those with Diabetes Mellitus4, with no significant difference in clinical event rates.
3. Circulation, 138, 00-00. DOI: 10.1161/CIRCULATIONAHA.118.038065
4. J Am Heart Assoc. 2021;10e020165 DOI:10.1161/JAHA.120.020165